Literature DB >> 19450337

Bronchiectasis.

Nick ten Hacken1, Huib Kerstjens, Dirkje Postma.   

Abstract

INTRODUCTION: Bronchiectasis is usually a complication of previous lower respiratory infection, and causes chronic cough and copious production of sputum, which is often purulent. Bronchiectasis may cause signs of chronic obstructive pulmonary disease. It can also be associated with cystic fibrosis and other congenital disorders, foreign body inhalation, and other causes of lung damage. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments in people with bronchiectasis but without cystic fibrosis? We searched: Medline, Embase, The Cochrane Library and other important databases up to July 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). We performed a GRADE evaluation of the quality of evidence for interventions.
RESULTS: We found 16 systematic reviews, RCTs, or observational studies that met our inclusion criteria.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: anticholinergic therapy, bronchopulmonary hygiene physical therapy, exercise or physical training, hyperosmolar agents (inhaled), leukotriene receptor antagonists, methyl-xanthines (oral), mucolytics (bromhexine or deoxyribonuclease), prolonged-use antibiotics, beta(2) agonists, steroids (inhaled, oral), and surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19450337      PMCID: PMC2907995     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  7 in total

Review 1.  Bronchiectasis: the 'other' obstructive lung disease.

Authors:  V Mysliwiec; J S Pina
Journal:  Postgrad Med       Date:  1999-07       Impact factor: 3.840

2.  Inhaled fluticasone in bronchiectasis: a 12 month study.

Authors:  K W Tsang; K C Tan; P L Ho; G C Ooi; J C Ho; J Mak; G L Tipoe; C Ko; C Yan; W K Lam; M Chan-Yeung
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

3.  Inhaled steroids improve quality of life in patients with steady-state bronchiectasis.

Authors:  Miguel A Martínez-García; Miguel Perpiñá-Tordera; Pilar Román-Sánchez; Juan Jose Soler-Cataluña
Journal:  Respir Med       Date:  2006-01-24       Impact factor: 3.415

4.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.

Authors:  A E O'Donnell; A F Barker; J S Ilowite; R B Fick
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

5.  Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa.

Authors:  L A Couch
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

6.  Bronchiectasis: an orphan disease with a poorly-understood prognosis.

Authors:  T Keistinen; O Säynäjäkangas; T Tuuponen; S L Kivelä
Journal:  Eur Respir J       Date:  1997-12       Impact factor: 16.671

7.  Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort.

Authors:  M B Nicotra; M Rivera; A M Dale; R Shepherd; R Carter
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

  7 in total
  1 in total

1.  Gastroesophageal reflux in bronchiectasis and the effect of anti-reflux treatment.

Authors:  Zhi-Wei Hu; Zhong-Gao Wang; Yu Zhang; Ji-Min Wu; Jian-Jun Liu; Fang-Fang Lu; Guang-Chang Zhu; Wei-Tao Liang
Journal:  BMC Pulm Med       Date:  2013-06-03       Impact factor: 3.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.